__NUXT_JSONP__("/drugs/Anlotinib_Hydrochloride", (function(a,b,c,d){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"1360460-82-7",chebiId:b,chemicalFormula:b,definition:"The hydrochloride salt form of anlotinib, a receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and anti-angiogenic activities. Upon administration, anlotininib targets multiple RTKs, including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3). This agent may both inhibit angiogenesis and halt tumor cell growth.",fdaUniiCode:"A3749M6582",identifier:"C106428",preferredName:c,semanticType:"Pharmacologic Substance",subclassOf:["C129825","C1742","C1967"],synonyms:["1-((4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolyl)oxymethyl)cyclopropanamine, Dihydrochloride","ALTN HCl",c,"CATEQUENTINIB DIHYDROCHLORIDE","Cyclopropanamine, 1-(((4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-, Hydrochloride (1:2)"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FAnlotinib_Hydrochloride",extension:".json",createdAt:d,updatedAt:d}}],fetch:{},mutations:void 0}}("Anlotinib_Hydrochloride","","Anlotinib Hydrochloride","2021-10-30T13:17:57.543Z")));